Sciele Pharma has extended a U.S. marketing agreement with sanofi-aventis for Allegra oral suspension by three years.

Under the terms of the agreement, which also covers the Allegra (fexofenadine HCl) orally disintegrating tablets, Sciele will be responsible for all sales and marketing associated with these products in the U.S. and will share the revenues. The company said it expects to launch the orally disintegrating tablets in March.

The disintegrating 30-mg tablet form of Allegra is indicated for treating seasonal allergy symptoms — such as sneezing, runny nose and itchy, watery eyes — as well as for treating uncomplicated skin manifestations of chronic idiopathic hives in children 6–11 years old.

Allegra oral suspension 30 mg/5 mL is indicated for treating allergy symptoms in children 2–11 years old and chronic idiopathic hives in children 6 months to 11 years old.